Lack of HER-2 gene amplification in non-Hodgkin lymphoma using chromogenic in situ hybridisation test.

about

High levels of topoisomerase IIalpha protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment.

P2860

Q43055705-1F4FD567-777D-4B22-89DC-F167B9556530

P2860

Lack of HER-2 gene amplification in non-Hodgkin lymphoma using chromogenic in situ hybridisation test.

Item

http://www.wikidata.org/entity/Q39978523

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Lack of HER-2 gene amplificati ...... ic in situ hybridisation test.

@en

Lack of HER-2 gene amplificati ...... ic in situ hybridisation test.

@nl

type

Item

label

Lack of HER-2 gene amplificati ...... ic in situ hybridisation test.

@en

Lack of HER-2 gene amplificati ...... ic in situ hybridisation test.

@nl

prefLabel

Lack of HER-2 gene amplificati ...... ic in situ hybridisation test.

@en

Lack of HER-2 gene amplificati ...... ic in situ hybridisation test.

@nl

P1476

Lack of HER-2 gene amplificati ...... ic in situ hybridisation test.

@en

P2093

Amram Hadary

http://www.w3.org/2001/XMLSchema#string

Anthony Gershuny

http://www.w3.org/2001/XMLSchema#string

Eli Gez

http://www.w3.org/2001/XMLSchema#string

Jamal Zidan

http://www.w3.org/2001/XMLSchema#string

Moshe Stein

http://www.w3.org/2001/XMLSchema#string

Sergio Szvalb

http://www.w3.org/2001/XMLSchema#string

P2860

The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer.

Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy.

Anticancer therapy targeting the erbB family of receptor tyrosine kinases.

Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma.

Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.

P304

736-740

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428190902801820

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19452317

http://www.w3.org/2001/XMLSchema#string

Lack of HER-2 gene amplification in non-Hodgkin lymphoma using chromogenic in situ hybridisation test.

about

P2860

P2860

Lack of HER-2 gene amplification in non-Hodgkin lymphoma using chromogenic in situ hybridisation test.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698